Dow Jones Top Company Headlines at 1 AM ET: Hyundai Motor, Union Reach Wage Deal to End Walkouts | Visa ...
MorningStar·- Hyundai Motor and its union reached a tentative wage deal to end production-disruptive walkouts, while Visa and Mastercard stocks hit record highs due to resilient U.S. consumer spending. - SpaceX plans to launch Nvidia-powered AI satellites by next year, and the FDA approved an Alzheimer's blood test developed by Roche and Eli Lilly. - The FTC reached an antitrust settlement with Zillow and Redfin, and the NHTSA expanded its investigation into GM's electronic braking system.Dow Jones Top Company Headlines at 3 PM ET: California Cancels Paramount Meeting, Citing Leaks | EV-Maker ...
MorningStar·- California canceled a settlement meeting regarding a multistate antitrust lawsuit concerning the Paramount and Warner merger due to leaks. - The FTC reached an antitrust settlement with Zillow and Redfin to unwind a prior $100 million market-sharing agreement. - Roche and Eli Lilly obtained FDA approval for a new Alzheimer's disease blood test.Pharmaceutical Stocks To Watch Now - August 23rd
Market Beat·- MarketBeat identified seven pharmaceutical stocks with the highest dollar trading volume to watch, including Eli Lilly, Merck, Johnson & Johnson, AbbVie, McKesson, Abbott Laboratories, and Pfizer. - These publicly traded companies engage in researching, developing, manufacturing, and selling medicines and healthcare products worldwide. - While offering growth potential from successful drug launches, these stocks also carry inherent risks such as clinical trial failures and regulatory decisions.Best Pharmaceutical Stocks To Watch Today - August 21st
Market Beat·- MarketBeat identified seven pharmaceutical stocks with the highest dollar trading volume to watch, including Eli Lilly, Merck, Johnson & Johnson, AbbVie, Pfizer, Abbott Laboratories, and Jupiter Neurosciences. - These publicly traded companies operate globally in discovering, developing, manufacturing, and selling prescription and over-the-counter medicines across diverse therapeutic areas. - While these pharmaceutical stocks offer growth potential through successful drug approvals and strong sales, they also carry inherent risks related to clinical trials, regulatory decisions, patents, and pricing pressures.